Computational methods for Target Fishing (TF), also known as Target Prediction or 7
where evaluating as many targets as possible is preferable, ligand-centric tools would be more 1 appealing, as these provide a much wider coverage of the proteome. 2 Unfortunately, it is unclear how well ligand-centric methods work in practice due to the 3 limitations of existing benchmarks. Some validations have been restricted to a few tens of ligand-4 rich targets using benchmarks borrowed from VS (AbdulHameed et al., 2012) and thus tell us very 5 little about how well the methods will perform on the many remaining targets. Furthermore, some 6 performance measures, such as the ROC (Receiver Operating Characteristic) AUC (Area Under 7 Curve), do not precisely measure TF performance. For example, how many true targets of a query 8 molecule one is likely to find in practice using a method that has obtained an average ROC AUC 9 of 0.7 over 40 targets? On the other hand, TF is often posed as a multi-category classification 10 problem, which formulates a binary classification problem per target and thus the variation of 11 predictive performance across query molecules has not been analysed in these studies. 12 Importantly, these benchmarks exclude many possible targets of the analysed molecules because 13 the corresponding target-centric models could not be trained on the excluded targets. As a result of 14 these limitations, current benchmarks offer little guidance on pragmatic questions such as how 15 many predicted targets have to be tested on average to find a true target, how many known targets 16 are typically missed or how such performance varies with the query molecule. 17 In this study, we propose a new benchmark to validate TF methods, which naturally lends 18 itself to answer such questions. This is based on formulating a binary classification problem for 19 each query molecule. From this new perspective, we provide a lower-bound for the current 20 performance of ligand-centric methods representing the minimum that can be expected nowadays 21 from them. As a byproduct, our analysis provides an update for the degree of polypharmacology Further requirements are commonly imposed for the measured bioactivity of a ligand against a 1 target to be counted as a known target for that ligand. First, the bioactivity measurement must be 2 of relatively high quality, activities.standard_type IN ('EC50', 'Ki', 'Kd', 'IC50') , which discards 3 percentages of inhibition among other lower-quality measurements. Second, only complexes with 4 a sufficiently potent bioactivity are retained (common activity thresholds are 1µM and 10µM 5 meaning that a ligand hitting any target with an activity higher than 10µM will not be considered 6 to be a target in neither of these two scenarios). Third, only targets with at least n qualifying 7 ligands are considered. For many target-centric methods, a sufficiently high number of ligands is 8 needed to build a model for the target, e.g. those methods based on similarity-ensemble 9 approaches (n=5) (Keiser et al., 2009) or multi-target QSAR (n=20) (Koutsoukas et al., 2013) . In 10 this study, we analyse ligand-centric methods, which can evaluate any target with at least a known 11 ligand (i.e. n=1) and hence result in a much broader search for targets (3,035 molecular targets 12 with 10µM). An analysis of the target coverage of TF methods is carried out in section 3.1. 13 14 Next, we partition each of the two n=1 datasets as follows. First, we identify the subset of 15 approved drugs. Second, we search for all those approved drugs in the ChEMBL database meeting 16 the criteria, with a suitable chemical structure available and hitting any of the targets introduced in 17 the previous section. These are the two approved-drugs sets of query molecules shown in Table 1 . 18 Third, we pick at random two further sets of molecules of the same size, which we called random-19 molecules sets. This will serve as a control group to investigate how target predictions for set of database molecules, which is the same for both sets of query molecules but different 1 between thresholds. Table 1 shows the four non-overlapping data partitions A-D (no query 2 molecule is included as database molecule too). 4 For our analysis, we selected a simple two-dimensional chemical similarity search (Willett, 2014) 5 in order to obtain a lower-bound for the performance of ligand-centric TF methods. This goal 6 requires selecting a simple method, rather than an optimal method which would be unlikely to 7 provide such lower-bound. Consequently, we selected the dice score on MACCS fingerprints ad 8 hoc, although there are of course other valid choices too. We started by generating MACCS 9 fingerprints (Durant et al.) for all query and database molecules in Table 1 . Each fingerprint 10 encodes the presence or absence of 166 predetermined chemical groups in the molecule as a 11 binary string of the same size. These were generated using the RDKit (Lamdrum).
Data partitions

A simple TF method to estimate a lower-bound for performance
12
As usual, fingerprints could not be generated for a few unusual molecules and consequently 13 queries could not be performed for these. This is the case of Gramidicin (CHEMBL1201469), 14 which is actually not a molecule but a mixture of three antibiotic compounds. Other examples are 15 some organometallic compounds such as the anti-rheumatic agent Auranofin (CHEMBL1366).
16
Table 1 compiles all selected molecules for which MACCS fingerprints could be generated. Using their MACCS fingerprints, the Dice score was used to measure the similarity between a 1 query molecule and all the database molecules. The Dice score is defined as:
where a is the number of on bits in molecule A, b is number of on bits in molecule B, while c is 3 the number of bits that are on at the same positions in both molecules. For each query, the top k 4 hits can be identified from the corresponding ranking of database molecules (these are the k 5 database molecules with the most similar chemical structure to that of the query molecule). We 6 consider here k = 1, 5, 10 and 15 to investigate the dependence of the method with its only control 7 parameter k.
8
Finally, the known targets for the k hits are retrieved from the ChEMBL database and returned 9 as predicted targets for the considered query molecule. Thus, a set of predicted targets is obtained 10 for each combination of query molecule and k value. Note that a known target is not just any 11 target annotated in the ChEMBL database, but one complying with the requirements set in section 12 2.1. for each of the four cases in only these could be comprehensively tested. As a result, any empirically untested target-ligand 1 association that is predicted to be a true association will have to be rejected as false, despite an 2 unknown part of these being actually true targets of the molecule. We must therefore keep in mind 3 that this retrospective validation represents a lower-bound for performance in this sense as well.
4 Table 2 shows the confusion matrix arising from assessing target predictions against 5 experimental evidence for each query molecule. After the assessment, each target prediction can 6 be classed in one of four categories: TP for True Positive (the predicted target is a known target); 7 TN for True Negative (the target was not predicted but anyway is not known to be a target); FP for 8 False Positive (the predicted target is not known to be a target, i.e. a false discovery or Type I 9 error); and FN for False Negative (the target was not predicted and it is actually a target, i.e. 10 missed discovery or Type II error).
11
From these quantities, we will calculate four performance measures per query molecule.
12
Accuracy is the proportion of correct target predictions:
13
(2)
Precision is the proportion of new targets that would be obtained after experimentally 14 validating the predictions of the method:
15 
Recall accounts for the proportion of true targets that the method has missed:
The Matthews Correlation Coefficient (MCC) captures both types of error in a single metric, 2 with higher values being better up to +1 (perfect classification):
Lastly, the Number of Predicted Targets (NPT) will be also reported to investigate how this 4 varies with the method"s control parameter k. The entire workflow is sketched in Figure 1 . 
Results and Discussion
1
Four key questions along with two representative case studies are addressed in this section. The 2 analysis is based on the performance obtained by the query molecules in the four datasets in Table   3 2, which will be summarised with boxplots of precision, recall, MCC and NPT. The first two rows of Table 3 show the number of targets considered by a ligand-centric TF 6 method with two target definitions (i.e. activity thresholds of 1µM and 10µM). The remaining 7 rows show the number of targets considered by exemplary target-centric methods as a result of 8 only considering targets with at least 5-40 ligands. To allow a fair comparison, we have calculated 9 the number of targets using the same selection criteria on chembl20 data (section 2.1), except for 10 the minimum number of ligands required by each method and the selected activity threshold.
11
For example, target-centric methods powered by models requiring at least 40 ligands per target 12 and defining a target with an activity threshold of 10µM would be predicting whether the query 13 molecule has activity against any of the 917 qualifying single-protein targets. In contrast, a ligand-14 centric method with the same activity threshold will be able to evaluate 2,118 targets more, for 15 which the first method is unable to provide any prediction by construction. Of course, the 1 advantage of target-centric over ligand-centric methods is that the former will tend to perform 2 better on those targets with a high number of ligands, which highlights the complementarity of 3 both approaches. It would be interesting if the performance of target-centric methods was 4 evaluated per target and analysed against its number of cognate ligands, as it is currently unknown 5 how reliable are their predictions on the many targets with only a few ligands above the minimum. there are also many non-molecular targets annotated in ChEMBL for this drug). On the right, we 5 can appreciate that approved drugs currently have an average of eight known targets with potency 6 better than 10µM, although the median number is three targets. This new estimate is based on 745 7 drugs and their 1,076 targets and it is two targets higher than previous estimates using less data 8 (802 drugs and 480 targets) (Mestres et al., 2009 ). However, the boxplot"s lower quartile value 9 indicates that at least 25% of these drugs have just one known target and thus seem very selective.
10
It is also noteworthy in Figure 2 that the number of annotated targets for the set of random 11 molecules is smaller than that for approved drugs, with four targets on average instead of eight.
12
This substantial difference is likely to be due to a much higher number of targets being tested 13 during the process of developing a drug. 
How many predicted targets have to be tested to find a true target?
15 Table 4 presents average performance results for approved drugs (set A), with the TF method 16 using four different k values. As k increases, Type I errors increase (lower precision) and Type II 17 errors decrease (higher recall). In other words, as more top hits are used to provide predicted 18 targets, fewer known targets are missed. However, this comes at the cost of having more false 19 positives, as target inferences are made using increasingly less similar database molecules. Using 20 the top 5 hits to predict targets (i.e. k=5) provides the best compromise between these conflictive objectives (i.e. the highest average MCC). This setting leads to 5.04 predicted targets on average 1 over these query molecules (note that each top hit may have more than one known target, but 2 collectively provide fewer targets because some of these are repeated in the set). Lastly, the very 3 high average accuracy values are due to each classification problem being highly unbalanced and 4 the method correctly discarding the vast majority of non-targets. Nevertheless, unlike precision 5 and recall, accuracy is not suitable to measure Type I and II errors and hence is not helpful to 6 address the investigated questions.
7 Figure 3 shows the distribution of the NPT across query molecules using k=5. By comparing it 8 with Figure 2 , it is observed that there are substantially more known targets than predicted targets 9 for approved drugs using the top 5 hits for predictions (this is not the case for the sets of random 10 molecules, where most query molecules have a higher number of predicted targets than of known 11 targets). is, despite the simplicity of the method and thanks to the wealth of data on which it relies, 8 only five predicted targets will have to be tested in order to find two true targets with potency 9 better than 1µM. In all cases, there is strong performance variability across the query 10 molecules, as it can be appreciated by the large interquartile range of each boxplot. For 11 instance, in set C, the predictions for the targets of 109 drugs are of the highest precision 12 (precision=1), those for other 216 drugs not precise at all (precision=0) and those for the 13 remaining 420 drugs have intermediate precision values (in other words, hit rates are neither 14 0% nor 100%). Also, the cases with a tighter activity threshold of 1µM are on average slightly 15 better predicted than their counterparts using 10µM. Specific cases with high-and low-random molecules obtained much better results than those with approved drugs. Thus, if we 1 order the four cases by average precision (dashed blue line in Figure 4) , this gives the 2 following performance hierarchy D>B>C>A (i.e. D obtains higher average precision than B, 3 B better than C and C better than A). Interestingly, this is the opposite ranking for the number 4 of known targets (A>C>B>D). In other words, those sets with a higher number of known 5 targets tend to be harder to predict. However, the cause of obtaining lower predictive accuracy with approved drugs is not their higher 12 number of known targets per se, but an underlying factor correlated with it: the query drug and its 13 top hits, which should include some of the chemical derivatives that eventually led to this drug, 14 often have a lower overlap in terms of known targets. One contributing factor for a low overlap is 15 that two similar chemical structures do not always have affinity for the same targets. There is 16 abundant literature analysing these pathological cases known as activity cliffs (Medina-Franco, this issue will become less frequent as more molecules are included in chemogenomics databases.
12
1
Another contributing factor is that some of the top hits could have been tested against a range of 2 targets in other studies, which might not have included the drug and thus this molecule would not 3 have been tested against the targets (a lower precision for this query molecule would be 4 consequently obtained, as such targets would be perceived as false positives). Importantly, while 5 these are not known targets of the drug, some are expected to become a known target once tested.
6
In contrast, a molecule from the randomly-chosen set often has a larger overlap with its top hits 7 (e.g. in set D, the predicted targets of 324 randomly-chosen molecules have precision=1, whereas 8 those for just 35 randomly-chosen molecules have precision=0). The latter cases are likely to arise 9 from a situation where a chemical series is investigated against a set of related targets to be later 10 abandoned (Waring et al., 2015) . This would explain the lower number of known targets and the 11 smaller predictive errors for these sets. 
How many known targets of the query molecule are typically missed? 13
Addressing this question is necessary to estimate how many discoveries are being missed by the 14 ligand-centric method, but it has not been investigated with regards to employed query molecule.
15 Figure 4 presents the results in terms of recall (middle plot). Looking at the recall boxplots, only 16 about 10% of the targets are on average missed in the sets of random molecules (i.e. recall~0.9), 17 whereas the mean of missed targets for approved drugs is about 65%. A large part of these missed 18 targets might be due to more intense research on the drug after approval than on its chemical 19 derivatives, leading to many targets being tested in the former but not the latter.
On the other hand, the MCC boxplots (Figure 4 right plot) show the distribution of the total error 1 across query molecules, with a high MCC necessarily meaning that the query molecule obtains 2 low levels of both Type I and II errors. The latter occurs to most random molecules regardless of 3 the activity threshold (almost 75% of these query molecules have MCCs higher than 0.6). In 4 contrast, only a small proportion of approved drugs are in this category. Again, the performance 5 hierarchy is D>B>C>A for both recall and MCC. Here, a higher number of known targets in the 6 query molecules is also correlated with the difficulty of predicting their targets, but this is also 7 explained by the different ways in which the query molecules and their hits were tested against 8 targets. 9 3.5. Representative case studies 10 Section 3.2 analysed the NKT across query molecules. As discussed in section 3.3, the NKT of a 11 molecule depends on its intrinsic polypharmacology, but also on how comprehensively the 12 molecule has been tested across targets by the relevant scientific communities (we will call 13 observed polypharmacology to the combination of these two factors). In the adopted TF method, 14 the NPT of a molecule is given by the NKTs from its top 5 hits according to the dice score on 15 MACCS fingerprints. Thus, the NPT for the query molecule depends in turn on the observed 16 polypharmacology of each of these hits. In this section, we analyse two approved drugs 17 representing cases where the difference in observed polypharmacology between the drug and its 18 top hits are large in one direction (NKT>>NPT) or the other (NKT<<NPT).
19
The first case has nilotinib as the query molecule. Nilotinib was presented as a small-molecule 20 selective tyrosine kinase inhibitor (Manley et al., 2010) . However, we now know that this marketed drug has at least NKT=67 known molecular targets under 10µM, of which 14 are not 1 kinases. In contrast, its top 5 hits collectively hit just nine targets (NPT=9). This is not surprising 2 given the intense research interest in nilotinib as a targeted drug for the treatment of imatinib-3 resistant Chronic Myeloid Leukemia (Breccia and Alimena, 2010) , but less so in its top hits from 4 database molecules containing no drugs by construction. Figure 5A illustrates the proposed 5 validation approach on nilotinib as the degree of overlap between the target spaces spanned by the 6 query molecule and its top hits. Since predicted targets can only be either a true target or not, TP + 7 FP = NPT. Likewise, known targets are either correctly predicted or not and thus TP + FN = NKT.
8
As explained in section 2.4, the hit rate is given precision=TP/NPT, thus precision=0.89. In other 9 words, the TF method retrospectively obtains an 89% hit rate for nilotinib (i.e. finding eight true 10 targets of nilotinib in nine predicted targets). However, 59 known targets of nilotinib are missed 11 by this method, as indicated by a low recall=TP/NKT of 0.12. This evidences that a method 12 offering a high hit rate, while highly satisfying from a cost-effectiveness perspective, must be 13 complemented by a high recall to be optimal. 14 Figure 5B shows the validation for the second case, which analyses the antimalarial agent 15 chloroquine. NKT=3, NPT=21, precision=0.05 and recall=0.33 are obtained in these case. This 16 represents a modest hit rate of just 5%, implying that a high experimental effort would have been 17 associated to this discovery. However, the method obtains a higher recall with chloroquine than 18 with nilotinib, which means that a lower proportion of known targets are being missed. There are a total of 21 FP target predictions in both query molecules. However, none of these 6 target-ligand pairs have actually been tested (i.e. no bioactivity associated to them in ChEMBL.
Conclusions
1
We have shown that ligand-centric techniques for TF are capable of considering up to thousands 2 of targets more than target-centric techniques. This important advantage means that ligand-centric 3 techniques have their niche in TF. We have also discussed the limitations of current benchmarks to 4 test TF methods and consequently we have designed a new benchmark that overcomes them.
5
Using the proposed benchmark, it has been possible to investigate how reliable are ligand-centric 6 methods for TF depending on the employed query molecule. Despite the simplicity of the adopted 7 method and owing to the wealth of data on which it relies, we have found that only five predicted 8 targets will have to be tested in order to find two true targets with potency better than 1µM on 9 average over marketed drugs. This level of performance is already useful for prospective 10 applications and it is encouraging that there is plenty of scope for methodological improvement.
11
The latter will be particularly needed to reduce the high number of false negatives, i.e. known 12 targets that are currently missed by ligand-centric techniques. It is worth noting that, while this 13 issue has not been investigated yet for target-centric techniques, the many targets not considered 14 by this class of techniques are by construction false negatives of any molecule that hits them. We 15 have argued that this drawback is hard to appreciate as target-centric techniques only report 16 predictive performance achieved on the typically much smaller set of considered targets. 17 The results for the set of randomly-selected molecules used as a control group are substantially 18 better than those for approved drugs. We have discussed how the different way in which targets 19 are tested against the query molecules and their top hits is the primary reason for this marked 20 difference. Since approved drugs have been presumably tested against many more targets, we have identified an average of eight known targets under 10µM in approved drugs, which 1 reinforces the notion that polypharmacology is a common and strong event. Lastly, high 2 performance variability across query molecules has been observed in all cases. Thus, a promising 3 avenue for future research consists in investigating which features make the target-ligand pair 4 more difficult to predict in order to assign a confidence score to each prediction. Mol. Inform. 33, 403-413. doi:10.1002/minf.201400024. 16 Yu, H., Chen, J., Xu, X., Li, Y., Zhao, H., Fang, Y., et al. (2012) . A systematic prediction of 17 multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS 
